Status:
COMPLETED
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vaccines, Pneumococcal
Eligibility:
All Genders
42-98 years
Phase:
PHASE3
Brief Summary
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy 2 month old infants
- Available for the duration of the study and reachable by telephone
- Able to complete two blood drawing procedures during the study
- Exclusion criteria:
- Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components
- Bleeding disorder, immune deficiency or significant chronic or congenital disease
- Previous receipt of blood products or immune globulin
Exclusion
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
1712 Patients enrolled
Trial Details
Trial ID
NCT00444457
Start Date
May 1 2007
End Date
June 1 2009
Last Update
October 15 2012
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Benton, Arkansas, United States, 72019
2
Conway, Arkansas, United States, 72033
3
Fayetteville, Arkansas, United States, 72703
4
Jonesboro, Arkansas, United States, 72401